Welcome!

News Feed Item

PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune™ Cancer Immunotherapy Platform in a Phase 1 Clinical Trial

NORTH BRUNSWICK, N.J., Feb. 11, 2014 /PRNewswire/ -- PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia.

The trial which is being conducted at three leading gynecological oncology centers in the United States is designed to evaluate the safety, feasibility and immunological responses of the novel Versamune-based PDS0101 cancer immunotherapy in patients with cervical intraepithelial neoplasia.

"The ability to effectively train and prime our body's immune system to specifically target and kill cancer cells has recently shown significant promise in treating various cancers," said Dr. Frank Bedu-Addo, CEO of PDS Biotechnology.  "Should the unique safety profile and efficacy of Versamune and PDS0101 demonstrated in preclinical studies be successfully replicated in humans, this will represent a significant advancement in the treatment of cancer. It would also represent a significant advancement in the treatment of early-stage cancer and certain infectious diseases where there is a high and growing unmet medical need not addressed by current approaches."

About PDS Biotechnology Corporation
PDS Biotechnology is a private biotechnology company applying its ground-breaking Versamune nanotechnology platform vector to the development of simpler, safer and more effective cancer immunotherapies and preventive vaccines.  PDS0101 is the company's lead cancer immunotherapy in development to treat HPV-induced cancers.  The company has a second cancer immunotherapy and pandemic influenza vaccine in the early stages of development. In 2012 PDS Biotechnology granted Merck KGaA a license to utilize the Versamune vector in two specific cancer immunotherapies.  For more information on PDS biotechnology please visit www.pdsbiotech.com.

About Versamune and PDS0101
PDS0101 is a cancer immunotherapy based on PDS Biotechnology's patented Versamune nanotechnology vector, and contains multiple unique sequences from a cancer causing strain of the human papillomavirus that have been modified to be more immunogenic.  

Versamune is based on certain structurally-specific lipids which possess unique immune modulating characteristics.  In preclinical studies Versamune was demonstrated to facilitate uptake and processing of the cancer proteins by the immune system.  It also enhanced successful priming and training of cancer-killing T-cells, and simultaneously reduced the population of immune suppressive cells leading to superior efficacy in eradicating the cancer in preclinical studies.  For more information on Versamune and how it works please visit www.pdsbiotech.com.

Cancers Caused by the Human papillomavirus
Patients diagnosed with the various HPV-induced cancers such as today have very limited treatment options, predominantly surgery, chemotherapy and radiation therapy.

Cervical intraepithelial neoplasia (CIN) is the abnormal growth of cells on the cervix.  A small percentage of CIN cases progress to become cervical cancer if left untreated.  The annual worldwide incidence is about 1.4 million.  The current treatment for high grade CIN involves removal of the cervical cells by methods such as loop electrical excision procedure (LEEP). The recurrence rate is reportedly about 20%, and surgical treatment is associated with an increased risk of infertility.

Oropharyngeal squamous cell carcinoma (OSCC): Over 70% of OSCC are estimated to be HPV-associated in Western countries.  It is predicted that the incidences of HPV-positive oral cancers will exceed the annual number of cervical cancer cases by 2020.

Cervical Cancer: It was estimated that in the US there would be over 12,000 newly diagnosed cases of cervical cancer in 2013.

SOURCE PDS Biotechnology Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Zerto will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clou...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
18th Cloud Expo, taking place June 7-9, 2016, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
@DevOpsSummit taking place June 7-9, 2016 at Javits Center, New York City, and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
SYS-CON Events announced today that IBM Cloud Data Services has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. IBM Cloud Data Services offers a portfolio of integrated, best-of-breed cloud data services for developers focused on mobile computing and analytics use cases.
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
How will your company move to the cloud while ensuring a solid security posture? Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is ...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.